How Some Manufacturers Are Navigating COVID-19 Pharma Supply Chain Challenges
Gilead, Vetter, Lonza and academic experts share what they’re focusing on to keep producing drugs during the pandemic.
You may also be interested in...
Experts describe the agile, localized supply chains that will emerge, only perhaps to be forgotten just-in-time for the next crisis.
FlexBiosys wins award; others to follow. New capacity may also benefit manufacture of monoclonal antibodies and cell and gene therapies.
US FDA is looking at risk-based approach for reporting changes in out-of-stock components such as plastic bioreactor bags, filters and tubing sets that are in short supply.